

Stephen T Sonis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/708213/publications.pdf>

Version: 2024-02-01

171
papers

13,674
citations

34105
52
h-index

22166
113
g-index

176
all docs

176
docs citations

176
times ranked

8378
citing authors

#	ARTICLE	IF	CITATIONS
1	Perspectives on cancer therapy-induced mucosal injury. Cancer, 2004, 100, 1995-2025.	4.1	1,214
2	The pathobiology of mucositis. Nature Reviews Cancer, 2004, 4, 277-284.	28.4	1,050
3	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, 120, 1453-1461.	4.1	838
4	Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 2007, 109, 820-831.	4.1	692
5	Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 2004, 100, 2026-2046.	4.1	691
6	Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2001, 19, 2201-2205.	1.6	552
7	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2020, 126, 4423-4431.	4.1	540
8	Management of Oral Mucositis in Patients Who Have Cancer. Dental Clinics of North America, 2008, 52, 61-77.	1.8	423
9	Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncology, 2009, 45, 1015-1020.	1.5	379
10	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer, 2008, 113, 2704-2713.	4.1	310
11	Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer, 1999, 85, 2103-2113.	4.1	305
12	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews, 2007, 33, 448-460.	7.7	235
13	A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer, 1993, 72, 1612-1617.	4.1	214
14	Mucositis. Current Opinion in Oncology, 2015, 27, 159-164.	2.4	213
15	T^h B¹ R^{ole for} N^{uclear} F^{actor} K^{appa} Bⁱⁿ D^{isease and its} P^{otential} I^{nvolvement in} M^{ucosal} I^{njury} A^{ssociated with} A^{nti-neoplastic} T^{herapy}. Critical Reviews in Oral Biology and Medicine, 2002, 13, 388-389.	4.4	189
16	Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemotherapy and Pharmacology, 2008, 62, 33-41.	2.3	179
17	Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Supportive Care in Cancer, 2016, 24, 2781-2792.	2.2	179
18	Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncology, 2009, 45, 164-172.	1.5	177

#	ARTICLE	IF	CITATIONS
19	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. <i>Blood</i> , 2002, 100, 3479-3482.	1.4	167
20	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017, 8, 354.	3.5	165
21	An animal model for mucositis induced by cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1990, 69, 437-443.	0.6	163
22	Oral mucositis. <i>Anti-Cancer Drugs</i> , 2011, 22, 607-612.	1.4	148
23	Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. <i>Supportive Care in Cancer</i> , 2007, 15, 491-496.	2.2	147
24	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 239-251.	2.3	147
25	Pathobiology of mucositis. <i>Seminars in Oncology Nursing</i> , 2004, 20, 11-15.	1.5	146
26	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 328-336.	2.0	136
27	How should we measure and report radiotherapy-induced xerostomia?. <i>Seminars in Radiation Oncology</i> , 2003, 13, 226-234.	2.2	135
28	Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. <i>Cancer</i> , 2010, 116, 210-215.	4.1	131
29	Emerging evidence on the pathobiology of mucositis. <i>Supportive Care in Cancer</i> , 2013, 21, 2075-2083.	2.2	121
30	Antimicrobial therapy to prevent or treat oral mucositis. <i>Lancet Infectious Diseases</i> , The, 2003, 3, 405-412.	9.1	115
31	Alterations in the Oral Mucosa Caused by Chemotherapeutic Agents.. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1981, 7, 1019-1025.	0.8	113
32	Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. <i>International Journal of Cancer</i> , 2016, 139, 2635-2645.	5.1	108
33	Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. <i>Cancer</i> , 2013, 119, 4268-4276.	4.1	107
34	Mucositis: biology and management. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2007, 15, 123-129.	1.8	104
35	Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host Disease Prophylaxis Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 383-388.	2.0	98
36	Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1979, 48, 21-28.	0.6	97

#	ARTICLE	IF	CITATIONS
37	Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. <i>Oral Oncology</i> , 2016, 54, 7-14.	1.5	92
38	Oral mucositis in cancer therapy. <i>The Journal of Supportive Oncology</i> , 2004, 2, 3-8.	2.3	88
39	Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1992, 74, 749-755.	0.6	83
40	Efficacy of Superoxide Dismutase Mimetic M40403 in Attenuating Radiation-Induced Oral Mucositis in Hamsters. <i>Clinical Cancer Research</i> , 2008, 14, 4292-4297.	7.0	79
41	Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3256-3265.	1.6	77
42	Risk factors affecting hospital length of stay in patients with odontogenic maxillofacial infections. <i>Journal of Oral and Maxillofacial Surgery</i> , 1996, 54, 1386-1391.	1.2	75
43	Oral pathoses as diagnostic indicators in leukemia. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1980, 50, 134-139.	0.6	70
44	Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1988, 65, 19-22.	0.6	63
45	Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 427-435.	0.8	63
46	Pharmacotherapy for the management of cancer regimen-related oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1801-1807.	1.8	61
47	A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1165-1172.	1.3	60
48	The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 57-77.	329.8	60
49	Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. <i>Frontiers in Pharmacology</i> , 2014, 5, 51.	3.5	59
50	Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. <i>Cancer</i> , 2014, 120, 1433-1440.	4.1	57
51	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	3.7	57
52	TRANSPLANTATION OF POLARIZED TYPE 2 DONOR T CELLS REDUCES MORTALITY CAUSED BY EXPERIMENTAL GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 1996, 62, 1278-1285.	1.0	57
53	Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e236-e240.	3.8	55
54	Oral complications of cancer therapy. <i>Oncology</i> , 2002, 16, 680-6; discussion 686, 691-2, 695.	0.5	53

#	ARTICLE	IF	CITATIONS
55	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. <i>Cancer</i> , 2003, 98, 406-412.	4.1	51
56	The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. <i>Cancer</i> , 1990, 66, 2375-2379.	4.1	50
57	Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-14.	3.0	48
58	New thoughts on the pathobiology of regimen-related mucosal injury. <i>Supportive Care in Cancer</i> , 2006, 14, 516-518.	2.2	47
59	Regimen-related gastrointestinal toxicities in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 26-30.	1.3	43
60	Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e236-e240.	3.8	43
61	Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. <i>Journal of Biotechnology</i> , 2016, 239, 115-125.	3.8	43
62	Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. <i>Core Evidence</i> , 2010, 4, 199.	4.7	42
63	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020, 28, 5059-5073.	2.2	40
64	Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. <i>Clinical Cancer Research</i> , 2003, 9, 3454-61.	7.0	40
65	Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. <i>Supportive Care in Cancer</i> , 2010, 18, 95-103.	2.2	39
66	In Vitro Effects of Isobutyl Cyanoacrylate on Four Types of Bacteria. <i>Journal of Dental Research</i> , 1971, 50, 1557-1558.	5.2	36
67	A clinically translatable mouse model for chemotherapy-related fatigue. <i>Comparative Medicine</i> , 2013, 63, 491-7.	1.0	36
68	Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1993, 76, 45-48.	0.6	35
69	Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. <i>Cancer Treatment Reviews</i> , 2015, 41, 122-128.	7.7	34
70	OUP accepted manuscript. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	2.1	34
71	Current understanding of the relationship between periodontal and systemic diseases. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 150-158.	1.1	30
72	Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. <i>International Journal of Radiation Biology</i> , 2008, 84, 401-412.	1.8	29

#	ARTICLE	IF	CITATIONS
73	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. <i>World Journal of Gastroenterology</i> , 2015, 21, 11793.	3.3	29
74	Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 675-680.	2.3	28
75	Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. <i>The Journal of Supportive Oncology</i> , 2007, 5, 231-5.	2.3	27
76	Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 1098-1103.	1.5	25
77	Design of Biomedical Robots for Phenotype Prediction Problems. <i>Journal of Computational Biology</i> , 2016, 23, 678-692.	1.6	25
78	The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis During Radiation Therapy. <i>EBioMedicine</i> , 2017, 18, 7-8.	6.1	25
79	The prevention and treatment of radiotherapy-induced xerostomia. <i>Seminars in Radiation Oncology</i> , 2003, 13, 302-308.	2.2	24
80	Disparities in Oral Cancer Screening Among Dental Professionals: NHANES 2011–2016. <i>American Journal of Preventive Medicine</i> , 2019, 57, 447-457.	3.0	24
81	Oral Medicine referrals at a hospital-based practice in the United States. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 119, 423-429.	0.4	23
82	Genomic risk prediction of aromatase inhibitor–related arthralgia in patients with breast cancer using a novel machine–learning algorithm. <i>Cancer Medicine</i> , 2018, 7, 240-253.	2.8	23
83	Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns. <i>Cancer</i> , 2018, 124, 760-768.	4.1	23
84	Oral complications of multimodality therapy for advanced squamous cell carcinoma of head and neck. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1986, 61, 139-141.	0.6	22
85	Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana–Farber Cancer Institute, 2011 to 2019. <i>Cancer</i> , 2021, 127, 1796-1804.	4.1	22
86	New Frontiers in Mucositis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 545-551.	3.8	21
87	Mammalian Target of Rapamycin Inhibitor–Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 503-508.	2.0	21
88	An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 541-548.	1.8	21
89	Genomic data integration in chronic lymphocytic leukemia. <i>Journal of Gene Medicine</i> , 2017, 19, e2936.	2.8	20
90	Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers. <i>Supportive Care in Cancer</i> , 2021, 29, 6061-6068.	2.2	20

#	ARTICLE	IF	CITATIONS
91	Oral lichen planus: comparative efficacy and treatment costs—a systematic review. BMC Oral Health, 2022, 22, 161.	2.3	20
92	Links between regimen-related toxicities in patients being treated for colorectal cancer. Current Opinion in Supportive and Palliative Care, 2009, 3, 50-54.	1.3	19
93	A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. Supportive Care in Cancer, 2012, 20, 1797-1804.	2.2	19
94	Chlorhexidine-Induced Lingual Keratosis and Dysplasia in Rats. Journal of Periodontology, 1978, 49, 585-591.	3.4	18
95	Effects of supernatants of polymorphonuclear neutrophils recruited by different inflammatory substances on mitogen responses of lymphocytes. Inflammation, 1982, 6, 1-11.	3.8	18
96	Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nature Clinical Practice Oncology, 2005, 2, 134-135.	4.3	18
97	Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. Current Problems in Cancer, 2016, 40, 244-257.	2.0	18
98	Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges. Current Opinion in Supportive and Palliative Care, 2018, 12, 198-210.	1.3	18
99	Biomarkers Associated with Lymphedema and Fibrosis in Patients with Cancer of the Head and Neck. Lymphatic Research and Biology, 2018, 16, 516-524.	1.1	18
100	A hypothesis for the pathogenesis of radiation-induced oral mucositis: when biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment. Supportive Care in Cancer, 2021, 29, 4939-4947.	2.2	18
101	Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis. Expert Opinion on Investigational Drugs, 2018, 27, 147-154.	4.1	17
102	Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Oral Diseases, 2022, 28, 9-22.	3.0	17
103	A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS ONE, 2016, 11, e0152995.	2.5	17
104	An analysis of dental services based in the emergency room. Special Care in Dentistry, 1988, 8, 106-108.	0.8	16
105	Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 253-260.	0.4	16
106	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 106, 320-328.	0.8	15
107	Superoxide Dismutase as an Intervention for Radiation Therapy-Associated Toxicities: Review and Profile of Avasopasem Manganese as a Treatment Option for Radiation-Induced Mucositis. Drug Design, Development and Therapy, 2021, Volume 15, 1021-1029.	4.3	15
108	Healing of Spontaneous Periodontal Defects in Dogs Treated with Xenogeneic Demineralized Bone. Journal of Periodontology, 1985, 56, 470-479.	3.4	14

#	ARTICLE	IF	CITATIONS
109	Preservation of the alveolar ridge with hydroxyapatite-collagen implants in rats. Journal of Prosthetic Dentistry, 1988, 60, 729-734.	2.8	14
110	Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnology Reports (Amsterdam, Netherlands), 2017, 15, 24-26.	4.4	14
111	Enhanced oral hygiene interventions as a risk mitigation strategy for the prevention of non-ventilator-associated pneumonia: a systematic review and meta-analysis. British Dental Journal, 2020, 228, 615-622.	0.6	14
112	Inflammation and Genetic Risk Indicators for Early Periodontitis in Adults. Journal of Periodontology, 2011, 82, 588-596.	3.4	13
113	Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Supportive Care in Cancer, 2015, 23, 433-439.	2.2	13
114	Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity?. Supportive Care in Cancer, 2020, 28, 423-424.	2.2	13
115	Treatment for Oral Mucositis—Current Options and an Update of Small Molecules Under Development. Current Treatment Options in Oncology, 2021, 22, 25.	3.0	12
116	Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 146-151.	0.4	11
117	The incidence of mast cells in selected oral lesions. Oral Surgery, Oral Medicine, and Oral Pathology, 1972, 34, 245-248.	0.6	10
118	MODIFICATION OF IN VITRO AND IN VIVO IMMUNE FUNCTION BY ACUTE INFLAMMATORY CELLS. Transplantation, 1980, 30, 244-250.	1.0	10
119	Utilization of inpatient dental consultation services. Special Care in Dentistry, 1981, 1, 18-21.	0.8	10
120	Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?. Journal of Oral Pathology and Medicine, 2016, 45, 469-474.	2.7	10
121	Genomics, Personalized Medicine, and Supportive Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 9-16.	3.8	9
122	Impact of Microarray Preprocessing Techniques in Unraveling Biological Pathways. Journal of Computational Biology, 2016, 23, 957-968.	1.6	9
123	The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis. Frontiers in Oral Health, 2021, 2, 689386.	3.0	8
124	Interaction of Ia antigen-bearing polymorphonuclear leukocytes and murine splenocytes. Inflammation, 1983, 7, 25-33.	3.8	7
125	In vivo and in vitro effects of β -carotene and algae extracts in murine tumor models. Nutrition and Cancer, 1989, 12, 371-380.	2.0	7
126	Effect of medical status on dental procedure time. Special Care in Dentistry, 1992, 12, 71-73.	0.8	7

#	ARTICLE	IF	CITATIONS
127	The Quest for Effective Treatments of Mucositis. The Journal of Supportive Oncology, 2011, 9, 170-171.	2.3	7
128	Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients. Journal of Pain and Symptom Management, 2017, 54, 326-339.	1.2	7
129	Severe oral hemorrhage and sepsis following bone marrow transplant failure. Oral Surgery, Oral Medicine, and Oral Pathology, 1983, 56, 483-486.	0.6	6
130	Single-Dose Prevention or Short-Term Treatment with Fibroblast Growth Factor-20 (CG53135-05) Reduces the Severity and Duration of Oral Mucositis. Supportive Cancer Therapy, 2005, 2, 122-127.	0.3	6
131	GM-1111 reduces radiation-induced oral mucositis in mice by targeting pattern recognition receptor-mediated inflammatory signaling. PLoS ONE, 2021, 16, e0249343.	2.5	6
132	Dimensional Stability of the Alveolar Ridge After Implantation of a Bioabsorbable Bone Graft Substitute: A Radiographic and Histomorphometric Study in Rats. Journal of Oral Implantology, 2005, 31, 68-76.	1.0	5
133	The Presence of Lymphoblasts in the Gingival Crevice of Children With Acute Lymphoblastic Leukemia. Journal of Periodontology, 1981, 52, 276-279.	3.4	4
134	Section Reviews: Biologicals & Immunologicals: Pharmacological attenuation of chemotherapy-induced oral mucositis. Expert Opinion on Investigational Drugs, 1996, 5, 1155-1162.	4.1	4
135	Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. Tumour Virus Research, 2022, 13, 200234.	3.8	4
136	Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation?. Nature Clinical Practice Oncology, 2006, 3, 244-245.	4.3	3
137	Benefits of the Involvement of Dentists in Managing Oral Complications Among Patients With Oral Cavity and Oropharyngeal Cancer: An Analysis of Claims Data. JCO Oncology Practice, 2021, 17, e1668-e1677.	2.9	3
138	Healthcare-associated infections among patients hospitalized for cancers of the lip, oral cavity and pharynx. Infection Prevention in Practice, 2021, 3, 100115.	1.3	3
139	An Outcomes Study of 40 Years of Graduates of a General Practice Dental Residency. Journal of Dental Education, 2015, 79, 888-896.	1.2	3
140	A Comparison and Assessment of Scoring Scales for Mucositis. , 2012, , 39-46.		3
141	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. Blood, 2004, 104, 351-351.	1.4	3
142	Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs).. Journal of Clinical Oncology, 2013, 31, 344-344.	1.6	3
143	THE ROLE OF EFFECTOR CELLS AND ANTISERUM IN THE INHIBITION OF CELL-MEDIATED CYTOTOXICITY OF ALLOGENEIC TUMOR CELLS. Transplantation, 1976, 22, 52-60.	1.0	2
144	The antigenicity of electrocauterized allogeneic tumor cells in mice. Journal of Surgical Research, 1982, 33, 17-22.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Increased efficiency of immunotherapy using irradiated tumor cells. Cancer Immunology, Immunotherapy, 1987, 24, 68-71.	4.2	2
146	Oral and Maxillofacial Medicine. Oral Diseases, 2009, 15, 118-118.	3.0	2
147	Network meta-analysis from a pairwise meta-analysis design: to assess the comparative effectiveness of oral care interventions in preventing ventilator-associated pneumonia in critically ill patients. Clinical Oral Investigations, 2021, 25, 2439-2447.	3.0	2
148	Exceptional toxicity resistance. Supportive Care in Cancer, 2021, 29, 2263-2264.	2.2	2
149	The application of “Omics” to accelerate precision medicine in Supportive Care in Cancer. Supportive Care in Cancer, 2021, 29, 7143-7144.	2.2	2
150	Significance of the head and neck in late infection in renal transplant recipients. Oral Surgery, Oral Medicine, and Oral Pathology, 1986, 62, 524-528.	0.6	1
151	Palifermin in Myelotoxic Therapy-Induced Oral Mucositis. Drugs, 2005, 65, 2147-2149.	10.9	1
152	Industry and MASCC “an opportunity not to be missed. Supportive Care in Cancer, 2021, 29, 559-561.	2.2	1
153	Community-based dental evaluation program for hematopoietic cell transplantation.. Journal of Clinical Oncology, 2013, 31, 143-143.	1.6	1
154	Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral Photobiomodulation. Diagnostics, 2021, 11, 2207.	2.6	1
155	Hospital dentistry: is there a future?. Special Care in Dentistry, 1987, 7, 243-243.	0.8	0
156	Manual of oral and maxillofacial surgery. Special Care in Dentistry, 1988, 8, 40-40.	0.8	0
157	Nanoparticulate Hydroxyapatite Enhances the Bioactivity of a Resorbable Bone Graft. Materials Research Society Symposia Proceedings, 2002, 735, 641.	0.1	0
158	Introduction; Oral Care in Advanced Disease; Supportive Care for the Renal Patient; Handbook of Opioid Bowel Syndrome Oral Care in Advanced Disease. Edited by Andrew Davies and Ilora Finley . New York: Oxford University Press, 2005, 221 pp., \$75.00 Supportive Care for the Renal Patient. Edited by E. Joanna Chambers , Michael Germain , and Edwina Brown . New York: Oxford University Press, 2004, 276 pp., \$95.00 (hardcover) Handbook of Opioid Bowel Syndrome. Edited by Chun-Su Yuan , M.D., Ph.D. Bin. Journal of Palliative Medicine, 2006, 9, 814-817.	1.1	0
159	Topical Clonazepam Solution for Management of Burning Mouth Syndrome. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 122, e110.	0.4	0
160	Extraorally delivered photobiomodulation therapy for prevention of oropharyngeal mucositis in pediatric patients undergoing hematopoietic cell transplantation. Proceedings of SPIE, 2017, , .	0.8	0
161	[P3&O91]: EFFECTIVE ANALYSIS OF GENE EXPRESSION FOR THE DISCOVERY OF BIOMARKERS AND THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE. Alzheimer’s and Dementia, 2017, 13, P968.	0.8	0
162	Disparities in the geospatial distribution of dentists in the United States in 2017. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 131, e114.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	1.4	0
164	Oral Mucositis (OM) and Outcomes of Allogeneic (AL) Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hematologic Malignancies.. Blood, 2005, 106, 3126-3126.	1.4	0
165	Oral Mucositis (OM) and Outcomes of Autologous (AU) Hematopoietic Stem Cell Transplantation (HSCT) Following High-Dose Melphalan (MP) Conditioning for Multiple Myeloma (MM).. Blood, 2005, 106, 1343-1343.	1.4	0
166	Reduced Infection and Mucositis In Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate.. Blood, 2010, 116, 3781-3781.	1.4	0
167	SNP-Based Bayesian Networks Define Oral Mucositis Risk in Patients Receiving Stomatotoxic Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 735-735.	1.4	0
168	Long-term symptom burden and orodental health of oropharyngeal cancer (OPC) survivors following treatment with chemoradiotherapy (CRT) or sequential therapy (ST).. Journal of Clinical Oncology, 2013, 31, 9530-9530.	1.6	0
169	Randomized double-blind placebo-controlled trial of celecoxib for radiation-induced oral mucositis.. Journal of Clinical Oncology, 2013, 31, 9620-9620.	1.6	0
170	New trends in the management of oral mucositis. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3 Suppl 1, S54-6.	4.9	0
171	An Outcomes Study of 40 Years of Graduates of a General Practice Dental Residency. Journal of Dental Education, 2015, 79, 888-96.	1.2	0